The abstract is read at the publisher; the summary is JClub's.
TANI label-free NIR-II autofluorescence imaging achieves high contrast (7.69 ± 0.52) for delineating human liver malignancies, with sensitivity 97.8% and specificity 98.4% across cancer types.
- Why it matters: Real-time intraoperative tools to reliably outline liver tumour boundaries are still difficult to achieve in routine clinical practice, limiting surgical accuracy.
- What they did: The team identified endogenous NIR-II (1,000–1,700 nm) autofluorescent substances abundant in human liver but negligible in cancerous tissue, then built the wide-field TANI imaging approach.
- The result: In delineating hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and liver metastasis from cirrhotic or non-cirrhotic livers, TANI outperformed visible (400–650 nm) or first NIR (700–900 nm) fluorescence-guided and conventional autofluorescence methods, maintaining performance across grade/stage, benign lesions, and blood/bile contamination.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.